Search Results
Sep 10, 2026, 08:17 ET Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Detection and MRD. HENDERSON, Nev., Sept. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract1 at the European Society of Medical
More news about: VolitionRx Limited
Aug 26, 2026, 09:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial
More news about: VolitionRx Limited
Aug 26, 2026, 08:17 ET Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
addressable market.HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a peer-reviewed paper and independent Editorial which reported
More news about: VolitionRx Limited
Aug 13, 2026, 16:10 ET VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
U.S. Eastern TimeHENDERSON, Nev., Aug. 13, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter of 2026. Volition
More news about: VolitionRx Limited
Aug 12, 2026, 08:17 ET Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results
More news about: VolitionRx Limited
Aug 11, 2026, 16:10 ET VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
a.m. U.S Eastern TimeHENDERSON, Nev., Aug. 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, August 14 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating
More news about: VolitionRx Limited
Aug 05, 2026, 08:17 ET Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
HENDERSON, Nev., Aug. 5, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived
More news about: VolitionRx Limited
Jul 30, 2026, 08:17 ET Volition Advances Nu.Q® NETs Platform Towards Commercialization
addressable marketHENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a
More news about: VolitionRx Limited
Jul 07, 2026, 08:17 ET VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value
More news about: VolitionRx Limited
Jun 17, 2026, 08:15 ET VolitionRx Announces Collaboration with Sysmex
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (
More news about: VolitionRx Limited
Jun 07, 2026, 18:30 ET VolitionRx Announces Pricing of $4.6 Million Public Offering
HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common
More news about: VolitionRx Limited
Jun 03, 2026, 08:12 ET VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic
More news about: VolitionRx Limited
May 27, 2026, 08:17 ET VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
HENDERSON, Nev., May 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial
More news about: VolitionRx Limited
May 14, 2026, 16:10 ET VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
HENDERSON, Nev., May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management
More news about: VolitionRx Limited
May 11, 2026, 08:19 ET VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
HENDERSON, Nev., May 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, May 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating
More news about: VolitionRx Limited
May 06, 2026, 08:17 ET VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy
More news about: VolitionRx Limited
Apr 29, 2026, 08:17 ET Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary
More news about: VolitionRx Limited
Apr 23, 2026, 08:12 ET VolitionRx Announces Acceptance of Compliance Plan by NYSE American
HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American")
More news about: VolitionRx Limited
Apr 20, 2026, 07:30 ET Volition Launches rNuQ™ Webshop Broadening Product Range
HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ
More news about: VolitionRx Limited
Apr 01, 2026, 12:26 ET VolitionRx krijgt 2,0 miljoen EUR aan niet-verwaterende financiering van regionale overheidsinstanties in België
HENDERSON, Nev., 1 april 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), een multinationaal bedrijf op het gebied van epigenetica, heeft een aanvullende financiering van € 2,0 miljoen (ongeveer $ 2,3 miljoen)
More news about: VolitionRx Limited
Mar 31, 2026, 21:27 ET VolitionRx obtient un financement non dilutif de 2 millions d'euros auprès d'organismes publics régionaux en Belgique
HENDERSON, Nev., 31 mars 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN : VNRX) (« Volition »), une multinationale spécialisée dans l'épigénétique, a obtenu un financement supplémentaire de 2 millions d'euros (environ 2,3 millions
More news about: VolitionRx Limited
Mar 31, 2026, 16:05 ET VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025. Volition
More news about: VolitionRx Limited
Mar 31, 2026, 08:16 ET VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest
More news about: VolitionRx Limited
Mar 30, 2026, 08:13 ET Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
HENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the
More news about: VolitionRx Limited
Mar 26, 2026, 08:17 ET Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen,
More news about: VolitionRx Limited